Suven declares dose administration of 1st patient in Phase 2A clinical trial of SUVN G-3031

25 Sep 2019 Evaluate

Suven Life Sciences has declared dose administration of the first patient in a Phase 2A clinical trial of SUVN G-3031, a Histamine H3 receptor inverse agonist in a Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of 2 mg and 4 mg SUVN-G3031 Compared to Placebo in Patients with Narcolepsy with or without Cataplexy.

The clinical development program being executed through Suven Neurosciences, Inc., a Delaware Company in USA, wholly owned subsidiary of Suven Life Sciences.

Suven Life Sciences is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies using GPCR targets.

Suven Life Sciences Share Price

139.45 -3.85 (-2.69%)
21-Jan-2026 12:19 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1621.10
Dr. Reddys Lab 1166.65
Cipla 1376.25
Zydus Lifesciences 880.70
Lupin 2161.05
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×